Form D · Biotechnology
Microbot Medical Inc.
Braintree, MA · CIK 0000883975
Offering snapshot reported Sep 30, 2025 · SEC filing
- Reported sold
- $25.2M Offering amount: $25.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 16, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 30, 2025 | Initial | $25,244,903 | No comparison | 1 | SEC filing |
| Feb 18, 2025 | Initial | $13,000,005 | No comparison | 5 | SEC filing |
| Jan 22, 2025 | Initial | $8,600,008 | No comparison | 5 | SEC filing |
| Jan 22, 2025 | Initial | $7,000,001 | No comparison | 5 | SEC filing |
| Jun 20, 2024 | Initial | $1,762,502 | No comparison | 3 | SEC filing |
| Jan 7, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Jan 7, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Jan 7, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 5, 2019 | Initial | $31,250 | No comparison | 2 | SEC filing |
| Dec 13, 2016 | Initial | $397,000,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.1M
- Finders' fees
- $0
- Form D file number
- 021-559180
The Total Offering Amount reflects the aggregate exercise price of the inducement preferred investment options and the exercise price of the placement agent preferred investment options.
In addition to the cash fee, the placement agent also received preferred investment options to purchase 1,342,694 shares of common stock at exercise prices ranging from of $1.875 - $2.6625 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. WAINWRIGHT & CO., LLC | 000000375 |
Source: Form D, filed Sep 30, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Ben Naim | Executive |
| Yoseph Bornstein | Director |
| Scott Burell | Director |
| Juan Diaz Cartelle | Executive |
| Juan Diaz Cartelle | Executive |
| Harel Gadot | Director, Executive |
| Yehezkel Himelfarb | Executive |
| Prattipati Laxminarain | Director |
| Pratipatti Laxminarain | Director |
| Martin Madden | Director |
| Solomon Mayer | Director |
| David Ben Naim | Executive |
| Simon Sharon | Executive |
| Moshe Shoham | Director |
| Aileen Stockburger | Director |
| Rachel Vaknin | Executive |
| Yoav Waizer | Director |
| Tal Wenderow | Director |
| David Wilson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
288 Grove Street Suite 388
Braintree, MA, 02184
Braintree, MA, 02184